My lab focuses on the development of bioresponsive nanomaterials that are delivered in vivo to harness biochemical cues in diseased tissue as triggers for disease readouts or site-specific therapeutic activity. We are especially interested in developing these tools to study, detect, and treat microbe-driven disease states (e.g. infections, microbiome dysbiosis, inflammation). Our goal is to develop solutions that can be readily translated at the point of care, for at-home use, or deployed for infectious disease surveillance to promote public health. To achieve this, we integrate nanomaterial design, chemical biology, and medicine and leverage collaborations with clinicians, immunologists, microbiologists, and other engineers.